10-Q: Xenetic Biosciences Q3 Loss Widens Amid R&D Boost

Xenetic Biosciences reported increased royalty revenue but a wider net loss for Q3 2025, driven by higher research and development expenses and legal costs, while initiating a strategic review.

Summary

• Net loss for the three months ended September 30, 2025, widened to $(509,940) from $(436,671) in the comparable prior-year period, an increase of 16.8%.
• Net loss for the nine months ended September 30, 2025, improved to $(2,101,784) from $(2,905,754) in the comparable prior-year period, a decrease of 27.7%.
• Royalty revenue for Q3 2025 increased by 67.2% to $1,026,957 from $614,243 in Q3 2024, primarily due to royalties from Takeda.
• Royalty revenue for the nine months ended September 30, 2025, increased by 19.4% to $2,210,115 from $1,851,464 in the comparable prior-year period.
• Research and development (R&D) expenses for Q3 2025 more than doubled, increasing by 105.6% to $(756,482) from $(367,985) in Q3 2024, driven by increased manufacturing development and pre-clinical research.
• General and administrative (G&A) expenses for Q3 2025 increased by 9.3% to $(815,209) from $(745,731) in Q3 2024, mainly due to increased legal costs related to the strategic review process.
• Cash balance decreased to $4,121,599 as of September 30, 2025, from $6,165,568 as of December 31, 2024.
• Working capital decreased by approximately $1.7 million to $4.0 million at September 30, 2025, from $5.7 million at December 31, 2024.
• The company initiated a formal strategic review process to explore alternatives to maximize shareholder value, including a potential sale or business combination.
• Subsequent to quarter end, on October 10, 2025, the company raised approximately $3.9 million in net proceeds from an underwritten public offering of common stock.

Sentiment

Score: 4

Explanation: The company shows mixed financial results with increased royalty revenue and an improved nine-month net loss, but a widening Q3 net loss and declining cash reserves. The ongoing strategic review introduces significant uncertainty and potential for substantial changes, including a reverse merger or sale, which could drastically alter the investment thesis. While a recent capital raise provides some short-term liquidity, the long-term capital needs and 'going concern' risk remain.

Positives

• Royalty revenue significantly increased by 67.2% for Q3 2025 to $1,026,957 and by 19.4% for the nine months ended September 30, 2025, to $2,210,115, primarily from the Takeda sublicense agreement.
• Net loss for the nine months ended September 30, 2025, decreased by 27.7% to $(2,101,784) compared to $(2,905,754) in the prior year, largely due to reduced G&A expenses over the nine-month period.
• General and administrative expenses for the nine months ended September 30, 2025, decreased by 21.4% to $(2,129,602) from $(2,710,670) in the prior year, mainly due to lower severance and benefits.
• A successful underwritten public offering subsequent to quarter end on October 10, 2025, raised approximately $3.9 million in net proceeds, providing additional liquidity.
• Management believes existing resources, combined with the recent capital raise, will be adequate to fund operations for at least twelve months from the date of the financial statement issuance.

Negatives

• Net loss for the three months ended September 30, 2025, widened by 16.8% to $(509,940) compared to $(436,671) in the same period last year.
• Cash balance declined significantly to $4,121,599 at September 30, 2025, from $6,165,568 at December 31, 2024.
• Working capital decreased by approximately $1.7 million to $4.0 million at September 30, 2025, from $5.7 million at December 31, 2024.
• Research and development expenses for Q3 2025 more than doubled, increasing by 105.6% to $(756,482) from $(367,985), indicating a higher cash burn rate for development activities.
• General and administrative expenses for Q3 2025 increased by 9.3% to $(815,209) from $(745,731), primarily due to increased legal costs associated with the strategic review process.
• Interest income, net, decreased by 49.8% for Q3 2025 and 47.4% for the nine months, due to lower average invested funds.
• The accumulated deficit increased to approximately $199.3 million at September 30, 2025, from $197.2 million at December 31, 2024, reflecting ongoing losses.
• The company continues to incur substantial losses since its inception and expects to continue to incur operating losses in the near-term.

Risks

• Uncertainty regarding the outcome and timing of the formal strategic review process, including the possibility that no strategic alternative will be undertaken or consummated.
• Potential for disruption to the business resulting from the strategic review process and potential adverse effects on the company's stock price.
• Risks and uncertainties related to the potential impacts of consummation of a strategic transaction on current business operations, strategy, and product development plans.
• Failure to realize the anticipated potential of the DNase technology.
• Inability to maintain compliance with the continued listing requirements of the Nasdaq Stock Market.
• Need to raise additional working capital in the future for further pipeline development and to continue as a going concern.
• Product development and commercialization risks, including the ability to successfully develop the DNase technology and secure regulatory approval.
• Impact of adverse safety outcomes and clinical trial results for therapies.
• Inability to secure and maintain a manufacturer for technologies.
• Impact of new therapies and new uses of existing therapies on the competitive environment.
• Reliance on consultants, advisors, vendors, and business partners to conduct work on the company's behalf.
• Impact of geopolitical events and global conflicts, including those in Ukraine and the Middle East, and associated sanctions, on economic markets and the company's business, financial condition, and results of operations.

Future Outlook

The company expects to continue incurring operating losses in the near-term and anticipates needing additional capital in the long-term to pursue its business initiatives. It believes it will continue to have access to capital resources through various means, including equity offerings, debt financings, corporate collaborations, or related party funding. The primary focus remains on advancing the systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. A formal strategic review process is ongoing to maximize shareholder value, considering options like a sale or business combination, but there is no assurance any transaction will be consummated.

Management Comments

• Management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued.
• The Company believes that its existing resources will be adequate to fund the Company’s operations for a period of at least twelve months from the date of the issuance of these financial statements.
• However, the Company anticipates it will need additional capital in the long-term to pursue its business initiatives.
• While the Company believes it will continue to have access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations, related party funding, or other means to continue as a going concern, the terms, timing and extent of any future financing will depend upon several factors.
• The Company remains committed to advancing its DNase technology and does not intend to make further announcements regarding the review process unless and until the Board approves a specific transaction or otherwise determines that further disclosure is appropriate.

Industry Context

Xenetic Biosciences operates within the highly competitive and volatile biopharmaceutical industry, specifically targeting immuno-oncology for difficult-to-treat cancers. Its proprietary DNase technology, designed to improve existing treatments by targeting neutrophil extracellular traps (NETs), positions it in a relevant area of cancer research. The company's initiation of a strategic review, including considering a reverse merger, is a common approach for smaller biotech firms seeking to enhance shareholder value, secure necessary capital, or gain access to broader resources in a challenging market environment. The noted volatility of capital markets for the biotech industry underscores the financial pressures faced by development-stage companies like Xenetic.

Comparison to Industry Standards

• No specific comparisons to industry benchmarks or comparable companies were provided in the filing.

Corporate Governance

Legal Proceedings

• Not currently subject to any material legal proceedings, nor is any material legal proceeding threatened against the company.
• May be a party to litigation and subject to claims incident to the ordinary course of business from time to time, but currently believes the final outcome of these matters will not have a material adverse effect on the business.

Related Party Transactions

• Paid Peri-Ness Ltd. approximately $83,000 during the nine months ended September 30, 2025, with approximately $50,000 recorded as an advanced payment and $9,000 in accounts payable as of September 30, 2025.
• No amounts were incurred in connection with agreements with Serum Institute of India and PJSC Pharmsynthez during the nine months ended September 30, 2025 and 2024.
• Entered into a Consulting Agreement with Dr. Dmitry Genkin, Chairman of the Board, effective January 1, 2025, to provide consulting services related to the DNase-based oncology program.
• Paid Dr. Genkin approximately $0.1 million during the three months and $0.3 million during the nine months ended September 30, 2025, for consulting services, with approximately $30,000 reflected within accounts payable as of September 30, 2025.
• Dr. Genkin does not receive any fees for his service as a member of the Board.

Stakeholder Impact

• Shareholders face potential significant impact from the ongoing strategic review, including possible dilution from future capital raises (like the recent $3.9 million offering) or changes in ownership structure if a business combination or reverse merger occurs. The uncertainty surrounding the review could also affect stock price volatility.
• Collaborators (Takeda, Catalent, Scripps Research, UVA) are impacted by continued engagement in research and development activities, with Takeda providing ongoing royalty revenue and the others involved in advancing the DNase technology, indicating continued commitment to product development.
• Creditors may be impacted by the company's liquidity position, which has seen a decrease in cash and working capital, though the recent capital raise provides some short-term relief.
• Employees and management are subject to potential changes stemming from the strategic review process, although no direct impacts or changes were detailed in the filing for the current period.

Next Steps

• Advance the systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
• Continue the formal strategic review process, considering alternatives such as a sale of all or part of the company or its assets, or a business combination (e.g., reverse merger).
• Potentially enter into definitive agreements for a strategic transaction, which would be subject to stockholder and Nasdaq approval.
• Continue research funding and collaboration with Scripps Research, with additional funding of approximately $0.3 million effective November 1, 2025, for extended and expanded services.
• Continue the University of Virginia (UVA) Agreement through December 2025 to investigate combinations of DNase I with immunotherapies in models of primary and metastatic colorectal cancer.

Key Dates

Recommendation

The company presents a mixed financial picture with increased royalty revenue and an improved nine-month net loss, but a widening Q3 net loss and declining cash reserves. The ongoing strategic review introduces significant uncertainty and potential for substantial changes, including a reverse merger or sale, which could drastically alter the investment thesis. While the recent capital raise provides short-term liquidity, the long-term capital needs and 'going concern' risk remain. Investors should hold and monitor the outcome of the strategic review and clinical progress of the DNase technology before making further investment decisions, as the risk/reward profile is currently balanced by both positive developments and significant uncertainties.

Keywords

Biopharmaceutical, Immuno-oncology, DNase technology, Pancreatic carcinoma, Solid tumors, Neutrophil extracellular traps, Strategic review, Reverse merger, Capital raise, Royalty revenue, Research and development, Nasdaq listing, Going concern, Takeda, Scripps Research, University of Virginia, Oncology, Biotech